1. Home
  2. NCMI vs PRTC Comparison

NCMI vs PRTC Comparison

Compare NCMI & PRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo National CineMedia Inc.

NCMI

National CineMedia Inc.

HOLD

Current Price

$3.82

Market Cap

414.7M

ML Signal

HOLD

Logo PureTech Health plc

PRTC

PureTech Health plc

HOLD

Current Price

$19.08

Market Cap

464.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NCMI
PRTC
Founded
2005
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Advertising
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
414.7M
464.3M
IPO Year
2007
N/A

Fundamental Metrics

Financial Performance
Metric
NCMI
PRTC
Price
$3.82
$19.08
Analyst Decision
Strong Buy
Analyst Count
4
0
Target Price
$6.63
N/A
AVG Volume (30 Days)
269.2K
2.9K
Earning Date
03-05-2026
08-28-2025
Dividend Yield
3.15%
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.20
Revenue
$236,300,000.00
$6,391,000.00
Revenue This Year
$3.27
N/A
Revenue Next Year
$11.61
N/A
P/E Ratio
N/A
$8.57
Revenue Growth
N/A
1265.60
52 Week Low
$3.68
$13.30
52 Week High
$7.25
$20.00

Technical Indicators

Market Signals
Indicator
NCMI
PRTC
Relative Strength Index (RSI) 42.71 52.17
Support Level $3.72 $17.31
Resistance Level $3.96 $18.82
Average True Range (ATR) 0.14 0.66
MACD 0.00 0.02
Stochastic Oscillator 30.00 34.47

Price Performance

Historical Comparison
NCMI
PRTC

About NCMI National CineMedia Inc.

National CineMedia Inc is a cinema advertising platform in the U.S. It derives revenue from the sale of advertising to national, regional and local businesses through The Noovie Show, the cinema advertising and entertainment show seen on movie screens across the U.S., on LEN, a series of strategically-placed screens located in movie theater lobbies, as well as other forms of advertising and promotions in theater lobbies.

About PRTC PureTech Health plc

PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.

Share on Social Networks: